Cargando…

Audit of principal investigator's compliance for submission of continue review application and decisions taken on lapses in validity of approval by the Institutional Ethics Committee at tertiary oncology center in Navi Mumbai

CONTEXT: A failure to obtain continued Institutional Ethics Committee (IEC) approval for the study before the expiry date assigned by the IEC is considered as “lapse of the IEC approval” to continue the study at the site by the Investigator. Considering this, we had conducted an audit of principal i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandekar, Bhavesh, Awatagiri, Kasturi, Kannan, Sadhana, Rane, Pallavi, Parikh, Prafulla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345251/
https://www.ncbi.nlm.nih.gov/pubmed/35928644
http://dx.doi.org/10.4103/picr.PICR_102_20
_version_ 1784761377648279552
author Bandekar, Bhavesh
Awatagiri, Kasturi
Kannan, Sadhana
Rane, Pallavi
Parikh, Prafulla
author_facet Bandekar, Bhavesh
Awatagiri, Kasturi
Kannan, Sadhana
Rane, Pallavi
Parikh, Prafulla
author_sort Bandekar, Bhavesh
collection PubMed
description CONTEXT: A failure to obtain continued Institutional Ethics Committee (IEC) approval for the study before the expiry date assigned by the IEC is considered as “lapse of the IEC approval” to continue the study at the site by the Investigator. Considering this, we had conducted an audit of principal investigators (PI ') compliance for Continuing Review Application (CRA) submission timelines and decision taken on the lapses in the validity of IEC approval continuation. AIM: The aim of this study is to assess the pre- and post-policy trends of non-compliance management of delayed CRA submission and compare the PI's compliance for submission of CRA between Investigator Initiated trial (IIT) and Pharma studies. SETTING AND DESIGN: The present study was a retrospective audit of CRAs of ongoing projects submitted by PIs to IEC, ACTREC. MATERIALS AND METHODS: The data from total 199 CRAs submitted for review to the IEC between the year January 2016 and December-2017 were collected and maintained in Microsoft Excel sheet, and later, the data were exported into the SPSS software version 21 for the analysis. STATISTICAL ANALYSIS: All categorical data were presented in numbers and percentage. The first primary objective was assessed by calculating the duration between the dates of approval for any study to the date of next CRA submission. The CRAs submitted after the project expiry date were considered as a lapse in following the IEC SOP. RESULTS: This retrospective audit revealed that CRA reminder sent by the IEC to the PI played an important role in compliance w. r. t timely in following the IEC SOPof the CRA by the PI. As a result, overall, 90% of CRAs showed compliance in submitting CRAs to IEC in both IIT and Pharma study. The number of lapses were reduced to 7 in the postpolicy period as compared to 15 lapses in the prepolicy period. CONCLUSION: This retrospective audit reveals that CRA reminder sent by the IEC to the PI played an important role in improving the compliance of PIs in submitting CRA to IEC. Each IEC should develop the policy to minimize the delays in CRA submission by the PI and prevent lapses in following the IEC SOP.
format Online
Article
Text
id pubmed-9345251
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-93452512022-08-03 Audit of principal investigator's compliance for submission of continue review application and decisions taken on lapses in validity of approval by the Institutional Ethics Committee at tertiary oncology center in Navi Mumbai Bandekar, Bhavesh Awatagiri, Kasturi Kannan, Sadhana Rane, Pallavi Parikh, Prafulla Perspect Clin Res Original Article CONTEXT: A failure to obtain continued Institutional Ethics Committee (IEC) approval for the study before the expiry date assigned by the IEC is considered as “lapse of the IEC approval” to continue the study at the site by the Investigator. Considering this, we had conducted an audit of principal investigators (PI ') compliance for Continuing Review Application (CRA) submission timelines and decision taken on the lapses in the validity of IEC approval continuation. AIM: The aim of this study is to assess the pre- and post-policy trends of non-compliance management of delayed CRA submission and compare the PI's compliance for submission of CRA between Investigator Initiated trial (IIT) and Pharma studies. SETTING AND DESIGN: The present study was a retrospective audit of CRAs of ongoing projects submitted by PIs to IEC, ACTREC. MATERIALS AND METHODS: The data from total 199 CRAs submitted for review to the IEC between the year January 2016 and December-2017 were collected and maintained in Microsoft Excel sheet, and later, the data were exported into the SPSS software version 21 for the analysis. STATISTICAL ANALYSIS: All categorical data were presented in numbers and percentage. The first primary objective was assessed by calculating the duration between the dates of approval for any study to the date of next CRA submission. The CRAs submitted after the project expiry date were considered as a lapse in following the IEC SOP. RESULTS: This retrospective audit revealed that CRA reminder sent by the IEC to the PI played an important role in compliance w. r. t timely in following the IEC SOPof the CRA by the PI. As a result, overall, 90% of CRAs showed compliance in submitting CRAs to IEC in both IIT and Pharma study. The number of lapses were reduced to 7 in the postpolicy period as compared to 15 lapses in the prepolicy period. CONCLUSION: This retrospective audit reveals that CRA reminder sent by the IEC to the PI played an important role in improving the compliance of PIs in submitting CRA to IEC. Each IEC should develop the policy to minimize the delays in CRA submission by the PI and prevent lapses in following the IEC SOP. Wolters Kluwer - Medknow 2022 2021-02-08 /pmc/articles/PMC9345251/ /pubmed/35928644 http://dx.doi.org/10.4103/picr.PICR_102_20 Text en Copyright: © 2021 Perspectives in Clinical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Bandekar, Bhavesh
Awatagiri, Kasturi
Kannan, Sadhana
Rane, Pallavi
Parikh, Prafulla
Audit of principal investigator's compliance for submission of continue review application and decisions taken on lapses in validity of approval by the Institutional Ethics Committee at tertiary oncology center in Navi Mumbai
title Audit of principal investigator's compliance for submission of continue review application and decisions taken on lapses in validity of approval by the Institutional Ethics Committee at tertiary oncology center in Navi Mumbai
title_full Audit of principal investigator's compliance for submission of continue review application and decisions taken on lapses in validity of approval by the Institutional Ethics Committee at tertiary oncology center in Navi Mumbai
title_fullStr Audit of principal investigator's compliance for submission of continue review application and decisions taken on lapses in validity of approval by the Institutional Ethics Committee at tertiary oncology center in Navi Mumbai
title_full_unstemmed Audit of principal investigator's compliance for submission of continue review application and decisions taken on lapses in validity of approval by the Institutional Ethics Committee at tertiary oncology center in Navi Mumbai
title_short Audit of principal investigator's compliance for submission of continue review application and decisions taken on lapses in validity of approval by the Institutional Ethics Committee at tertiary oncology center in Navi Mumbai
title_sort audit of principal investigator's compliance for submission of continue review application and decisions taken on lapses in validity of approval by the institutional ethics committee at tertiary oncology center in navi mumbai
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345251/
https://www.ncbi.nlm.nih.gov/pubmed/35928644
http://dx.doi.org/10.4103/picr.PICR_102_20
work_keys_str_mv AT bandekarbhavesh auditofprincipalinvestigatorscomplianceforsubmissionofcontinuereviewapplicationanddecisionstakenonlapsesinvalidityofapprovalbytheinstitutionalethicscommitteeattertiaryoncologycenterinnavimumbai
AT awatagirikasturi auditofprincipalinvestigatorscomplianceforsubmissionofcontinuereviewapplicationanddecisionstakenonlapsesinvalidityofapprovalbytheinstitutionalethicscommitteeattertiaryoncologycenterinnavimumbai
AT kannansadhana auditofprincipalinvestigatorscomplianceforsubmissionofcontinuereviewapplicationanddecisionstakenonlapsesinvalidityofapprovalbytheinstitutionalethicscommitteeattertiaryoncologycenterinnavimumbai
AT ranepallavi auditofprincipalinvestigatorscomplianceforsubmissionofcontinuereviewapplicationanddecisionstakenonlapsesinvalidityofapprovalbytheinstitutionalethicscommitteeattertiaryoncologycenterinnavimumbai
AT parikhprafulla auditofprincipalinvestigatorscomplianceforsubmissionofcontinuereviewapplicationanddecisionstakenonlapsesinvalidityofapprovalbytheinstitutionalethicscommitteeattertiaryoncologycenterinnavimumbai